Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs

Pharmaceutical Research

Volumn 29, Issue 4, 2012, Pages 1098-1109

  Dixon, Andrew S ^a   Constance, Jonathan E ^a   Tanaka, Tomoyuki ^b   Rabbitts, Terence H ^b   Lim, Carol S ^a  

^a UNIVERSITY OF UTAH   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Intracellular domain antibody; Oncoprotein; Subcellular targeting

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN;

ANIMAL CELL; ANTIBODY STRUCTURE; ARTICLE; BINDING AFFINITY; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; APOPTOSIS; BINDING SITES; CELL GROWTH PROCESSES; CELL NUCLEUS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84862685624     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0654-8     Document Type: Article

References (45)

1. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest. 1993;92(4):1925-39.
2. Dhut S, Chaplin T, Young BD. BCR-ABL and BCR proteins: biochemical characterization and localization. Leukemia. 1990;4 (11):745-50.
3. Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A. 1998;95(13):7457-62.
4. Vella V, Zhu J, Frasca F, Li CY, Vigneri P, Vigneri R, et al. Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem. 2003;278(27):25151-7.
5. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19(49):5643-50.
6. Zhu J, Wang JY. Death by Abl: a matter of location. Curr Top Dev Biol. 2004;59:165-92.
7. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-34.
8. Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, Lim CS. Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. J Control Release. 2009;140(3):245-9.
9. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-9.
10. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341 (6242):544-6.
11. Tanaka T, Lobato MN, Rabbitts TH. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol. 2003;331(5): 1109-20.
12. Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A. 2004;101(51):17616-21.
13. Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther. 2005;4(11):1801-9.
14. Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet. 2006;15(1):105-11.
15. Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J, Pandey S. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. Faseb J. 2006;20(14):2636-8.
16. Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology. 2009;49(1):39-49.
17. Tanaka T, Rabbitts TH. Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J Mol Biol. 2008;376(3):749-57.
18. Visintin M, Quondam M, Cattaneo A. The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation. Methods. 2004;34(2):200-14.
19. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002;317 (1):73-83.
20. Tanaka T, Rabbitts TH. Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture. Nat Protoc.5(1):67-92.
21. Tanaka T, Sewell H, Waters S, Phillips SE, Rabbitts TH. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J Biol Chem. Feb 4;286(5):3707-16.
22. Preyer M, Vigneri P, Wang JY. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One.6(2):e17020.
23. Hantschel O, Wiesner S, Guttler T, Mackereth CD, Rix LL, Mikes Z, et al. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell. 2005;19(4):461-73.
24. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 1993;12 (4):1533-46.
25. Kin Y, Li G, Shibuya M, Maru Y. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome. J Biol Chem. 2001;276(42):39462-8.
26. McWhirter JR, Wang JY. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene. 1997;15 (14):1625-34.
27. Lemmon MA, Ferguson KM. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem J. 2000;350(Pt 1):1-18.
28. Lemmon MA, Ferguson KM, Abrams CS. Pleckstrin homology domains and the cytoskeleton. FEBS Lett. 2002;513(1):71-6.
29. Lemmon MA, Ferguson KM, O'Brien R, Sigler PB, Schlessinger J. Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc Natl Acad Sci U S A. 1995;92(23):10472-6.
30. Lemmon MA. Pleckstrin homology (PH) domains and phosphoinositides. Biochem Soc Symp. 2007;74:81-93.
31. Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham 3rd TE, et al. Disruption of Bcr-Abl coiled coil oligomerization by design. J Biol Chem. 2011;286(31):27751-60.
32. Taylor CM, Keating AE. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain. Biochemistry. 2005;44(49):16246-56.
33. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002;9(2):117-20.
34. Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, et al. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 1997;6 (6):773-82.
35. Lim YM, Wong S, Lau G, Witte ON, Colicelli J. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc Natl Acad Sci U S A. 2000;97(22):12233-8.
36. Han L, Wong D, Dhaka A, Afar D, White M, Xie W, et al. Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc Natl Acad Sci U S A. 1997;94(10):4954-9.
37. Kakar M, Davis JR, Kern SE, Lim CS. Optimizing the protein switch: altering nuclear import and export signals, and ligand binding domain. J Control Release. 2007;120(3):220-32.
38. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224(Pt 3):213-32.
39. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J. 2004;86(6):3993-4003.
40. Dixon AS, Lim CS. The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain. Biotechniques. 2010;49(1):519-24.
41. Kanwal C, Mu S, Kern SE, Lim CS. Bidirectional on/off switch for controlled targeting of proteins to subcellular compartments. J Control Release. 2004;98(3):379-93.
42. Kakar M, Cadwallader AB, Davis JR, Lim CS. Signal sequences for targeting of gene therapy products to subcellular compartments: the role of CRM1 in nucleocytoplasmic shuttling of the protein switch. Pharm Res. 2007;24(11):2146-55.
43. Thai M, Ting PY, McLaughlin J, Cheng D, Muschen M, Witte ON, et al. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011;25(2):290-300.
44. Cao X, Tanis KQ, Koleske AJ, Colicelli J. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatorymechanisms. J Biol Chem. 2008;283(46):31401-7.
45. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13(12):7587-95.